towards improved death receptor targeted therapy for ... - TI Pharma

p38 and JNK induction by TRAIL
20. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C et al. Preclinical emergence
of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms
underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011;
105(10):1542‐1553.
21. Voortman J, Resende TP, bou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non‐
small cell lung cancer cells: sensitization to death receptor‐mediated apoptosis by
proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6(7):2103‐2112.
22. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular
determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor‐related
apoptosis‐inducing ligand. J Biol Chem 2005; 280(49):40599‐40608.
23. Krishna M, Narang H. The complexity of mitogen‐activated protein kinases (MAPKs) made
simple. Cell Mol Life Sci 2008; 65(22):3525‐3544.
24. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. SP600125, an
anthrapyrazolone inhibitor of Jun N‐terminal kinase. Proc Natl Acad Sci U S A 2001;
98(24):13681‐13686.
25. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D et al. Pyridinyl
imidazole inhibitors of p38 mitogen‐activated protein kinase bind in the ATP site. J Biol
Chem 1997; 272(18):12116‐12121.
26. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR et al. Structural basis of
inhibitor selectivity in MAP kinases. Structure 1998; 6(9):1117‐1128.
27. Degterev A, Hitomi J, Germscheid M,
Ch'en IL, Korkina O, Teng X et al. Identification of RIP1
kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4(5):313‐321.
28. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy
triggers apoptosis in
a caspase‐8‐dependent and mitochondria‐controlled manner in the non‐small cell lung
cancer cell line NCI‐H460. Cancer Res 2000; 60(24):7133‐7141.
29. Son JK, Varadarajan S, Bratton SB. TRAIL‐activated stress kinases suppress apoptosis
through transcriptional upregulation of MCL‐1. Cell Death Differ 2010; 17(8):1288‐1301.
30. Trouillas M, Saucourt C, Duval D, Gauthereau X, Thibault C,
Dembele D et al. Bcl2, a
transcriptional target of p38alpha, is critical for neuronal commitment of mouse embryonic
stem cells. Cell Death Differ 2008; 15(9):1450‐1459.
31. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor
targeting therapies for non‐small cell lung cancer: current status and perspectives. Drug
Resist Updat 2010; 13(1‐2):2‐15.
32. Zhang L, Fang B. Mechanisms of resistance to TRAIL‐induced apoptosis in cancer. Cancer
Gene Ther 2005; 12(3):228‐237.
33. Cargnello M, Roux PP. Activation
and function of the MAPKs and their substrates, the
MAPK‐activated protein kinases. Microbiol Mol Biol Rev 2011; 75(1):50‐83.
34. Festjens N, Vanden Berghe T, Cornelis
S, Vandenabeele P. RIP1, a kinase on the crossroads
of a cell's decision to live or die. Cell Death Differ 2007; 14(3):400‐410.
35. Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP
by caspase‐8
prompts TNF‐induced apoptosis. Genes Dev 1999; 13(19):2514‐2526.
36. Martinon F, Holler N, Richard C, Tschopp J. Activation of a pro‐apoptotic
amplification loop
through inhibition of NF‐kappaB‐dependent survival signals by caspase‐mediated
inactivation of RIP. FEBS Lett 2000; 468(2‐3):134‐136.
37. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S et al. The death domain kinase
RIP is essential for TRAIL (Apo2L)‐induced activation of IkappaB kinase and c‐Jun N‐terminal
kinase. Mol Cell Biol 2000; 20(18):6638‐6645.
38. Thomas LW, Lam C, Edwards SW. Mcl‐1; the molecular regulation of protein function. FEBS
Lett 2010; 584(14):2981‐2989.
39. Zhong Q, Gao W, Du F, Wang X. Mule/ARF‐BP1,
a BH3‐only E3 ubiquitin ligase, catalyzes
the polyubiquitination of Mcl‐1 and regulates apoptosis. Cell 2005; 121(7):1085‐1095.
‐ 57 ‐